2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

 

  • Daskapan, A., Idrus, L. R., Postma, M. J., Wilffert, B., Kosterink, J. G. W., Stienstra, Y., Touw, D. J., Andersen, A. B., Bekker, A., Denti, P., Hemanth Kumar, A. K., Jeremiah, K., Kwara, A., McIlleron, H., Meintjes, G., van Oosterhout, J. J., Ramachandran, G., Rockwood, N., Wilkinson, R. J., … Alffenaar, J. W. C. (2018). A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs. Clinical Pharmacokinetics, 0123456789. https://doi.org/10.1007/s40262-018-0716-8
     
  • Svensson, E. M., Yngman, G., Denti, P., McIlleron, H., Kjellsson, M. C., & Karlsson, M. O. (2018). Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy. Clinical Pharmacokinetics, 57(5), 591–599. https://doi.org/10.1007/s40262-017-0577-6
     
  • Sekaggya-Wiltshire, C., von Braun, A., Lamorde, M., Ledergerber, B., Buzibye, A., Henning, L., Musaazi, J., Gutteck, U., Denti, P., de Kock, M., Jetter, A., Byakika-Kibwika, P., Eberhard, N., Matovu, J., Joloba, M., Muller, D., Manabe, Y. C., Kamya, M. R., Corti, N., … Fehr, J. S. (2018). Delayed Sputum Culture Conversion in Tuberculosis–Human Immunodeficiency Virus–Coinfected Patients With Low Isoniazid and Rifampicin Concentrations. Clinical Infectious Diseases, 67(5), 708–716. https://doi.org/10.1093/cid/ciy179
     
  • de Kock, M., Tarning, J., Workman, L., Allen, E. N., Tekete, M. M., Djimde, A. A., Bell, D. J., Ward, S. A., Barnes, K. I., & Denti, P. (2018). Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: a Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria. Antimicrobial Agents and Chemotherapy, 62(5), e01370-17. https://doi.org/10.1128/AAC.01370-17
     
  • van der Laan, L. E., Garcia-Prats, A. J., Schaaf, H. S., Tikiso, T., Wiesner, L., de Kock, M., Winckler, J., Norman, J., McIlleron, H., Denti, P., & Hesseling, A. C. (2018). Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 62(2), e00420-17. https://doi.org/10.1128/AAC.00420-17
     
  • Denti, P., Garcia-Prats, A. J., Draper, H. R., Wiesner, L., Winckler, J., Thee, S., Dooley, K. E., Savic, R. M., McIlleron, H. M., Schaaf, H. S., & Hesseling, A. C. (2018). Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 62(2), e01521-17. https://doi.org/10.1128/AAC.01521-17
     
  • Innes, S., van der Laan, L., Anderson, P. L., Cotton, M., & Denti, P. (2018). Can we improve stavudine’s safety profile in children? Pharmacokinetics of intracellular stavudine triphosphate with reduced dosing. Antimicrobial Agents and Chemotherapy, 62(11), e00761-18. https://doi.org/10.1128/AAC.00761-18
     
  • Brunschwig, C., Lawrence, N., Taylor, D., Abay, E., Njoroge, M., Basarab, G. S., Le Manach, C., Paquet, T., Cabrera, D. G., Nchinda, A. T., De Kock, C., Wiesner, L., Denti, P., Waterson, D., Blasco, B., Leroy, D., Witty, M. J., Donini, C., Duffy, J., … Chibale, K. (2018). Uct943, a next-generation plasmodium falciparum pi4k inhibitor preclinical candidate for the treatment of malaria. Antimicrobial Agents and Chemotherapy, 62(9), e00012-18. https://doi.org/10.1128/AAC.00012-18
     
  • Chirehwa, M. T., McIlleron, H., Wiesner, L., Affolabi, D., Bah-Sow, O., Merle, C., Denti, P., & the RAFA team. (2018). Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid. Journal of Antimicrobial Chemotherapy, 74(1), 139–148. https://doi.org/10.1093/jac/dky378
     
  • Ali, A. M., Penny, M. A., Smith, T. A., Workman, L., Sasi, P., Adjei, G. O., Aweeka, F., Kiechel, J.-R., Jullien, V., Rijken, M. J., McGready, R., Mwesigwa, J., Kristensen, K., Stepniewska, K., Tarning, J., Barnes, K. I., & Denti, P. (2018). Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing. Antimicrobial Agents and Chemotherapy, 62(10), e02193-17. https://doi.org/10.1128/AAC.02193-17
     
  • Schalkwijk, S., ter Heine, R., Colbers, A. C., Huitema, A. D. R., Denti, P., Dooley, K. E., Capparelli, E., Best, B. M., Cressey, T. R., Greupink, R., Russel, F. G. M., Mirochnick, M., & Burger, D. M. (2018). A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women. Clinical Pharmacokinetics, 57(11), 1421–1433. https://doi.org/10.1007/s40262-018-0642-9
     
  • Pillai, G., Chibale, K., Constable, E. C., Keller, A. N., Gutierrez, M. M., Mirza, F., Sengstag, C., Masimirembwa, C., Denti, P., Maartens, G., Ramsay, M., Ogutu, B., Makonnen, E., Gordon, R., Ferreira, C. G., Goldbaum, F. A., Degrave, W. M. S., Spector, J., Tadmor, B., & Kaiser, H. J. (2018). The Next Generation Scientist program: capacity-building for future scientific leaders in low- and middle-income countries. BMC Medical Education, 18(1), 233. https://doi.org/10.1186/s12909-018-1331-y